These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 28072830)
21. Candidate early predictive plasma protein markers of doxorubicin-induced chronic cardiotoxicity in B6C3F Desai VG; Lee T; Moland CL; Vijay V; Han T; Lewis SM; Herman EH; Fuscoe JC Toxicol Appl Pharmacol; 2019 Jan; 363():164-173. PubMed ID: 30517846 [TBL] [Abstract][Full Text] [Related]
22. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. Swain SM; Whaley FS; Gerber MC; Ewer MS; Bianchine JR; Gams RA J Clin Oncol; 1997 Apr; 15(4):1333-40. PubMed ID: 9193324 [TBL] [Abstract][Full Text] [Related]
23. Cardioprotective effect of dexrazoxane during treatment with doxorubicin: a study using low-dose dobutamine stress echocardiography. Paiva MG; Petrilli AS; Moisés VA; Macedo CR; Tanaka C; Campos O Pediatr Blood Cancer; 2005 Dec; 45(7):902-8. PubMed ID: 16035077 [TBL] [Abstract][Full Text] [Related]
24. Erythropoietin modulates imbalance of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in doxorubicin-induced cardiotoxicity. Chen X; Guo Z; Wang P; Xu M Heart Lung Circ; 2014 Aug; 23(8):772-7. PubMed ID: 24685074 [TBL] [Abstract][Full Text] [Related]
25. Resveratrol significantly improves cell survival in comparison to dexrazoxane and carvedilol in a h9c2 model of doxorubicin induced cardiotoxicity. Monahan DS; Flaherty E; Hameed A; Duffy GP Biomed Pharmacother; 2021 Aug; 140():111702. PubMed ID: 34015579 [TBL] [Abstract][Full Text] [Related]
26. Dexrazoxane Protects Cardiomyocyte from Doxorubicin-Induced Apoptosis by Modulating miR-17-5p. Yu X; Ruan Y; Shen T; Qiu Q; Yan M; Sun S; Dou L; Huang X; Wang Q; Zhang X; Man Y; Tang W; Jin Z; Li J Biomed Res Int; 2020; 2020():5107193. PubMed ID: 32190669 [TBL] [Abstract][Full Text] [Related]
27. A concise description of cardioprotective strategies in doxorubicin-induced cardiotoxicity. Ludke AR; Al-Shudiefat AA; Dhingra S; Jassal DS; Singal PK Can J Physiol Pharmacol; 2009 Oct; 87(10):756-63. PubMed ID: 19898559 [TBL] [Abstract][Full Text] [Related]
28. Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits. Jirkovský E; Lenčová-Popelová O; Hroch M; Adamcová M; Mazurová Y; Vávrová J; Mičuda S; Šimůnek T; Geršl V; Štěrba M Toxicology; 2013 Sep; 311(3):191-204. PubMed ID: 23831762 [TBL] [Abstract][Full Text] [Related]
29. Cardioprotective effect of dexrazoxane in a rat model of myocardial infarction: anti-apoptosis and promoting angiogenesis. Zhou L; Sung RY; Li K; Pong NH; Xiang P; Shen J; Ng PC; Chen Y Int J Cardiol; 2011 Oct; 152(2):196-201. PubMed ID: 20692056 [TBL] [Abstract][Full Text] [Related]
30. [Dexrazoxane in patients with B-lymphomas or acute leukemias in the 2nd complete remission enables further therapy with cardiotoxic anthracyclines over recommended cumulative doses]. Lemez P; Stejskal J; Cahová S; Holub M; Svítil P; Maresová J; Vásová I; Boudová L; Benesová V; Dvoráková D; Fisar J; Slavícek L Vnitr Lek; 2004 Jun; 50(6):438-46. PubMed ID: 15346637 [TBL] [Abstract][Full Text] [Related]
31. Spinochrome D Attenuates Doxorubicin-Induced Cardiomyocyte Death via Improving Glutathione Metabolism and Attenuating Oxidative Stress. Yoon CS; Kim HK; Mishchenko NP; Vasileva EA; Fedoreyev SA; Stonik VA; Han J Mar Drugs; 2018 Dec; 17(1):. PubMed ID: 30577438 [TBL] [Abstract][Full Text] [Related]
32. Protective effects of mito-TEMPO against doxorubicin cardiotoxicity in mice. Rocha VC; França LS; de Araújo CF; Ng AM; de Andrade CM; Andrade AC; Santos Ede S; Borges-Silva Mda C; Macambira SG; Noronha-Dutra AA; Pontes-de-Carvalho LC Cancer Chemother Pharmacol; 2016 Mar; 77(3):659-62. PubMed ID: 26712129 [TBL] [Abstract][Full Text] [Related]
33. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. Venturini M; Michelotti A; Del Mastro L; Gallo L; Carnino F; Garrone O; Tibaldi C; Molea N; Bellina RC; Pronzato P; Cyrus P; Vinke J; Testore F; Guelfi M; Lionetto R; Bruzzi P; Conte PF; Rosso R J Clin Oncol; 1996 Dec; 14(12):3112-20. PubMed ID: 8955656 [TBL] [Abstract][Full Text] [Related]
34. Protective effect of Azadirachta indica a. Juss against doxorubicin-induced cardiac toxicity in tumour bearing mice. Koul A; Goyal R; Bharati S Indian J Exp Biol; 2014 Apr; 52(4):323-31. PubMed ID: 24772935 [TBL] [Abstract][Full Text] [Related]
35. (1)H NMR based metabolomic profiling revealed doxorubicin-induced systematic alterations in a rat model. Niu QY; Li ZY; Du GH; Qin XM J Pharm Biomed Anal; 2016 Jan; 118():338-348. PubMed ID: 26595282 [TBL] [Abstract][Full Text] [Related]
36. The Protective Role of Phenolic Compounds Against Doxorubicin-induced Cardiotoxicity: A Comprehensive Review. Razavi-Azarkhiavi K; Iranshahy M; Sahebkar A; Shirani K; Karimi G Nutr Cancer; 2016; 68(6):892-917. PubMed ID: 27341037 [TBL] [Abstract][Full Text] [Related]
37. Doxorubicin-induced Cardiotoxicity and Cardioprotective Agents: Classic and New Players in the Game. Dos Santos Arruda F; Tomé FD; Miguel MP; de Menezes LB; Nagib PRA; Campos EC; Soave DF; Celes MRN Curr Pharm Des; 2019; 25(2):109-118. PubMed ID: 30864503 [TBL] [Abstract][Full Text] [Related]
38. Molecular mechanisms of doxorubicin-induced cardiotoxicity: novel roles of sirtuin 1-mediated signaling pathways. Wang A J; Zhang J; Xiao M; Wang S; Wang B J; Guo Y; Tang Y; Gu J Cell Mol Life Sci; 2021 Apr; 78(7):3105-3125. PubMed ID: 33438055 [TBL] [Abstract][Full Text] [Related]